Literature DB >> 29855655

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease.

David Pineles1, Lisa Malter2, Peter S Liang3, Amy Arsuaga4, Brian Bosworth1,4, David P Hudesman4, Shannon Chang5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29855655     DOI： 10.1007/s00228-018-2492-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists.

Authors:  Eline van Overbeeke; Birgit De Beleyr; Jan de Hoon; Rene Westhovens; Isabelle Huys
Journal:  BioDrugs       Date:  2017-10       Impact factor: 5.807

2.  Patient attitudes and understanding about biosimilars: an international cross-sectional survey.

Authors:  Ira Jacobs; Ena Singh; K Lea Sewell; Ahmad Al-Sabbagh; Lesley G Shane
Journal:  Patient Prefer Adherence       Date:  2016-05-26       Impact factor: 2.711

3.  The nocebo effect challenges the non-medical infliximab switch in practice.

Authors:  N W Boone; L Liu; M J Romberg-Camps; L Duijsens; C Houwen; P H M van der Kuy; R Janknegt; R Peeters; R B M Landewé; B Winkens; A A van Bodegraven
Journal:  Eur J Clin Pharmacol       Date:  2018-01-24       Impact factor: 2.953
  3 in total
  1 in total

Review 1.  The Clinical Implications of Nocebo Effects for Biosimilar Therapy.

Authors:  Luana Colloca; Remo Panaccione; T Kevin Murphy
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.